Updated:
Natera
Dedicated to oncology, women’s health, and organ health. Natera’s cell-free DNA tests help protect health and inform more personalized decisions about care.
Natera
Dedicated to oncology, women’s health, and organ health. Natera’s cell-free DNA tests help protect health and inform more personalized decisions about care.
General information
Firm type
other
Year founded
2004
Location
Region
North America
Country
United States
City
San Carlos
Corporate office
San Carlos, CA, United States
Additional offices
Austin, TX, United States
Principals
Matthew Rabinowitz
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at Natera?
Natera is not an investment firm but a molecular diagnostics company. Investment decisions are made by the CEO and board, prioritizing clinical trial funding and commercial expansion. The firm does not manage third-party capital or operate as a family office.
Does Natera participate in fund commitments or only direct operations?
Natera is a diagnostics company, not a fund. It does not make fund commitments or direct investments as a limited partner. Its capital deployment is entirely operational—R&D, laboratory infrastructure, and commercial sales.
What clinical areas does Natera focus on?
Natera operates in three clinical areas: oncology (using the Signatera™ ctDNA test for molecular residual disease monitoring), women's health (Panorama™ noninvasive prenatal testing), and organ health (Prospera™ donor-derived cfDNA for transplant rejection monitoring). These are supported by a pipeline of large prospective studies.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: